Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dissect a pair of disappointing clinical results from newfangled ideas in biotech, discussing what each means — and doesn’t mean — for the future. Then, blogger Derek Lowe joins us to talk about his disagreement with Rep. Alexandria Ocasio-Cortez on the relationship between publicly funded research and industry-marketed drugs, a conversation that touches on science, policy, and sexism. Finally, STAT Washington correspondent Lev Facher calls in to discuss the slate of candidates lined up to challenge President Trump in 2020 and the ideas they bring to the world of drug pricing.
For more on what we cover, here’s the news on Solid Biosciences; here’s the story on Sangamo Therapeutics; and here’s Lowe’s blog post.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
